{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:31Z","timestamp":1794047431921,"version":"4.8.0"},"reference-count":123,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The last decade has seen steadfast progress in drug development in acute myeloid leukemia (AML) which has moved progressively towards genomic-based therapy. With these advances, outcomes in AML have improved but remains far from satisfactory. One approach towards preventing relapse in AML is to use maintenance therapy in patients, after attaining remission. Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective post-remission therapy that has been proven to reduce the risk of relapse. However, in patients who are ineligible for HSCT or have a high risk of relapse, other effective measures to prevent relapse are needed. There is also a need for post-HSCT maintenance to reduce relapse in high-risk subsets. Over the last 3 decades maintenance therapy in AML has evolved from the use of chemotherapeutic agents to more targeted therapies and better modulation of the immune system. Unfortunately, improvements in survival outcomes as a result of using these agents have not been consistently demonstrated in clinical trials. To derive the optimum benefit from maintenance therapy the time points of therapy initiation need to be defined and therapy must be selected precisely with respect to the AML genetics and risk stratification, prior treatment exposure, transplant eligibility, expected toxicity and the patient\u2019s clinical profile and desires. The far-reaching goal is to facilitate patients with AML in remission to achieve a normal quality of life while improving remission duration and overall survival. The QUAZAR trial was a welcome step towards a safe maintenance drug that is easy to administer and showed survival benefit but leaves many open issues for discussion. In this review we will discuss these issues, highlighting the development of AML maintenance therapies over the last 3 decades.<\/jats:p>","DOI":"10.3324\/haematol.2022.281810","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:54:51Z","timestamp":1683168891000},"page":"2289-2304","source":"Crossref","is-referenced-by-count":29,"title":["Maintenance therapy in acute myeloid leukemia: advances and controversies"],"prefix":"10.3324","volume":"108","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"51010","doi-asserted-by":"crossref","unstructured":"Cooperrider JH, Shukla N, Nawas MT, Patel AA. The cup runneth over: treatment strategies for newly diagnosed acute myeloid leukemia. JCO Oncol Pract. 2022; 19(2):74-85.","DOI":"10.1200\/OP.22.00342"},{"key":"51011","doi-asserted-by":"crossref","unstructured":"Short NJ, Zhou S, Fu C. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020; 6(12):1890-1899.","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"51012","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Kadia T, DiNardo C. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021; 11(2):41.","DOI":"10.1038\/s41408-021-00425-3"},{"key":"51013","doi-asserted-by":"crossref","unstructured":"Burnett AK, Russell NH, Hills RK. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013; 31(27):3360-3368.","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"51014","doi-asserted-by":"crossref","unstructured":"Koreth J, Schlenk R, Kopecky KJ. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22):2349-2361.","DOI":"10.1001\/jama.2009.813"},{"key":"51015","doi-asserted-by":"crossref","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022; 36(7):1749-1758.","DOI":"10.1038\/s41375-022-01591-4"},{"key":"51016","doi-asserted-by":"crossref","unstructured":"Sanz MA, Fenaux P, Tallman MS. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15):1630-1643.","DOI":"10.1182\/blood-2019-01-894980"},{"key":"51017","doi-asserted-by":"crossref","unstructured":"Wei AH, D\u00f6hner H, Pocock C. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020; 383(26):2526-2537.","DOI":"10.1056\/NEJMoa2004444"},{"key":"51018","doi-asserted-by":"crossref","unstructured":"Jen EY, Wang X, Li M. FDA approval summary: oral azacitidine for continued treatment of adults with acute myeloid leukemia unable to complete intensive curative therapy. Clin Cancer Res. 2022; 28(14):2989-2993.","DOI":"10.1158\/1078-0432.CCR-21-4525"},{"key":"51019","doi-asserted-by":"crossref","unstructured":"Perissinotti AJ, Benitez LL, Marini BL. Oral azacitidine maintenance for acute myeloid leukemia. N Engl J Med. 2021; 384(13):e51.","DOI":"10.1056\/NEJMc2101283"},{"key":"51020","doi-asserted-by":"crossref","unstructured":"Kadia TM, Reville PK, Wang X. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022; 40(33):3848-3857.","DOI":"10.1200\/JCO.21.02823"},{"key":"51021","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"51022","doi-asserted-by":"crossref","unstructured":"Wei AH, Panayiotidis P, Montesinos P. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022; 140(25):2754-2756.","DOI":"10.1182\/blood.2022016963"},{"key":"51023","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767.","DOI":"10.1182\/blood.2021013626"},{"key":"51024","doi-asserted-by":"crossref","unstructured":"Burnett AK, Russell NH, Hills RK. A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; 125(25):3878-3885.","DOI":"10.1182\/blood-2015-01-623447"},{"key":"51025","doi-asserted-by":"crossref","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361(13):1235-1248.","DOI":"10.1056\/NEJMoa0901409"},{"key":"51026","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Steffen B, Schliemann C. Single versus double induction with &quot;7+3&quot; containing 60 versus 90 mg daunorubicin for newly diagnosed AML: results from the randomized controlled SAL dauno-double trial. Blood. 2022; 140(Suppl 1):523-525.","DOI":"10.1182\/blood-2022-157126"},{"key":"51027","doi-asserted-by":"crossref","unstructured":"Krug U, Berdel WE, Gale RP. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia. 2016; 30(6):1230-1236.","DOI":"10.1038\/leu.2016.25"},{"key":"51028","unstructured":"Burnett A, Russell N, Freeman S. A comparison of limited consolidation chemotherapy therapy or not, and demethylation maintenance or not in older patients with AML and high risk MDS: long term results of the UK NCRI AML16 trial. Haematologica. 2015; 100(Suppl 1):194."},{"key":"51029","doi-asserted-by":"crossref","unstructured":"Huls G, Chitu DA, Havelange V. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019; 133(13):1457-1464.","DOI":"10.1182\/blood-2018-10-879866"},{"key":"51030","doi-asserted-by":"crossref","unstructured":"Sauter C, Fopp M, Imbach P. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984; 323(8373):379-382.","DOI":"10.1016\/S0140-6736(84)90424-0"},{"key":"51031","doi-asserted-by":"crossref","unstructured":"B\u00fcchner T, Urbanitz D, Hiddemann W. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985; 3(12):1583-1589.","DOI":"10.1200\/JCO.1985.3.12.1583"},{"key":"51032","doi-asserted-by":"crossref","unstructured":"Robles C, Kim KM, Oken MM. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group trial (E5483). Leukemia. 2000; 14(8):1349-1353.","DOI":"10.1038\/sj.leu.2401850"},{"key":"51033","doi-asserted-by":"crossref","unstructured":"Johnson SA, Prentice AG, Phillips MJ. Treatment of acute myeloid leukaemia with early intensive induction therapy. Acta Oncol. 1988; 27(5):527-529.","DOI":"10.3109\/02841868809093582"},{"key":"51034","doi-asserted-by":"crossref","unstructured":"L\u00f6wenberg B, Suciu S, Archimbaud E. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998; 16(3):872-881.","DOI":"10.1200\/JCO.1998.16.3.872"},{"key":"51035","doi-asserted-by":"crossref","unstructured":"Perel Y, Auvrignon A, Leblanc T. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89\/91. J Clin Oncol. 2002; 20(12):2774-2782.","DOI":"10.1200\/JCO.2002.07.300"},{"key":"51036","doi-asserted-by":"crossref","unstructured":"Malkovsk\u00fd M, Sondel PM. Interleukin 2 and its receptor: structure, function and therapeutic potential. Blood Rev. 1987; 1(4):254-266.","DOI":"10.1016\/0268-960X(87)90027-0"},{"key":"51037","doi-asserted-by":"crossref","unstructured":"Maraninchi D, Blaise D, Viens P. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 1991; 78(9):2182-2187.","DOI":"10.1182\/blood.V78.9.2182.bloodjournal7892182"},{"key":"51038","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995; 86(5):2041-2050.","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"51039","unstructured":"Speletas M, Ritis K, Bourikas G. Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2. Haematologica. 1996; 81(4):346-348."},{"key":"51040","unstructured":"Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia. 1996; 10(3):478-482."},{"key":"51041","doi-asserted-by":"crossref","unstructured":"Schliemann C, Gutbrodt KL, Kerkhoff A. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res. 2015; 3(5):547-556.","DOI":"10.1158\/2326-6066.CIR-14-0179"},{"key":"51042","doi-asserted-by":"crossref","unstructured":"Decot V, Voillard L, Latger-Cannard V. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol. 2010; 38(5):351-362.","DOI":"10.1016\/j.exphem.2010.02.006"},{"key":"51043","doi-asserted-by":"crossref","unstructured":"Sievers EL, Lange BJ, Sondel PM. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1998; 16(3):914-919.","DOI":"10.1200\/JCO.1998.16.3.914"},{"key":"51044","unstructured":"Blaise D, Attal M, Reiffers J. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw. 2000; 11(1):91-98."},{"key":"51045","doi-asserted-by":"crossref","unstructured":"Kolitz JE, Hars V, DeAngelo DJ. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients &lt; 60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. Blood. 2007; 110(11):157.","DOI":"10.1182\/blood.V110.11.157.157"},{"key":"51046","doi-asserted-by":"crossref","unstructured":"Baer MR, George SL, Caligiuri MA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008; 26(30):4934-4939.","DOI":"10.1200\/JCO.2008.17.0472"},{"key":"51047","doi-asserted-by":"crossref","unstructured":"Lange BJ, Smith FO, Feusner J. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(3):1044-1053.","DOI":"10.1182\/blood-2007-04-084293"},{"key":"51048","doi-asserted-by":"crossref","unstructured":"Pautas C, Merabet F, Thomas X. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010; 28(5):808-814.","DOI":"10.1200\/JCO.2009.23.2652"},{"key":"51049","doi-asserted-by":"crossref","unstructured":"Petit A, Ducassou S, Leblanc T. Maintenance therapy with interleukin-2 for childhood AML: results of ELAM02 phase III randomized trial. Hemasphere. 2018; 2(6):e159.","DOI":"10.1097\/HS9.0000000000000159"},{"key":"51050","doi-asserted-by":"crossref","unstructured":"Buyse M, Squifflet P, Lange BJ. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011; 117(26):7007-7013.","DOI":"10.1182\/blood-2011-02-337725"},{"key":"51051","doi-asserted-by":"crossref","unstructured":"Mao C, Fu XH, Yuan JQ. Interleukin\u20102 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database Syst Rev. 2015(11):CD010248.","DOI":"10.1002\/14651858.CD010248.pub2"},{"key":"51052","doi-asserted-by":"crossref","unstructured":"Aurelius J, Martner A, Brune M. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica. 2012; 97(12):1904-1908.","DOI":"10.3324\/haematol.2012.066399"},{"key":"51053","doi-asserted-by":"crossref","unstructured":"Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol. 1996; 57(4):312-319.","DOI":"10.1111\/j.1600-0609.1996.tb01383.x"},{"key":"51054","doi-asserted-by":"crossref","unstructured":"Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood. 2000; 96(5):1961-1968.","DOI":"10.1182\/blood.V96.5.1961"},{"key":"51055","doi-asserted-by":"crossref","unstructured":"Brune M, Castaigne S, Catalano J. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006; 108(1):88-96.","DOI":"10.1182\/blood-2005-10-4073"},{"key":"51056","doi-asserted-by":"crossref","unstructured":"Palva IP, Almqvist A, Elonen E. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. Eur J Haematol. 1991; 47(3):229-233.","DOI":"10.1111\/j.1600-0609.1991.tb01560.x"},{"key":"51057","doi-asserted-by":"crossref","unstructured":"Jiang H, Liu X-H, Kong J. Interferon-\u03b1 as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leuk Lymphoma. 2021; 62(12):2949-2956.","DOI":"10.1080\/10428194.2021.1948027"},{"key":"51058","doi-asserted-by":"crossref","unstructured":"Jackson GH, Davies FE, Pawlyn C. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20(1):57-73.","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"51059","doi-asserted-by":"crossref","unstructured":"Abou Dalle I, Kantarjian HM, Ravandi F. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021; 127(11):1894-1900.","DOI":"10.1002\/cncr.33409"},{"key":"51060","doi-asserted-by":"crossref","unstructured":"L\u00f6wenberg B, Pabst T, Maertens J. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021; 5(4):1110-1121.","DOI":"10.1182\/bloodadvances.2020003855"},{"key":"51061","doi-asserted-by":"crossref","unstructured":"Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Abedi M. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021; 56(12):2975-2980.","DOI":"10.1038\/s41409-021-01444-1"},{"key":"51062","doi-asserted-by":"crossref","unstructured":"Ansell SM, Lesokhin AM, Borrello I. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"51063","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Ramchandren R, Santoro A. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021; 22(4):512-524.","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"51064","doi-asserted-by":"crossref","unstructured":"Jain N, Senapati J, Thakral B. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023; 7(10):1958-1966.","DOI":"10.1182\/bloodadvances.2022008790"},{"key":"51065","doi-asserted-by":"crossref","unstructured":"Robert C, Schachter J, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372(26):2521-2532.","DOI":"10.1056\/NEJMoa1503093"},{"key":"51066","doi-asserted-by":"crossref","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801.","DOI":"10.1038\/s41467-020-17670-y"},{"key":"51067","doi-asserted-by":"crossref","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018; 8(9):1069-1086.","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"51068","doi-asserted-by":"crossref","unstructured":"Reville PK, Kantarjian HM, Ravandi F. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021; 11(3):60.","DOI":"10.1038\/s41408-021-00453-z"},{"key":"51069","doi-asserted-by":"crossref","unstructured":"Liu H, Sharon E, Karrison TG. Randomized phase II study to assess the role of nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (NCI9706 protocol; REMAIN trial). Blood. 2022; 140(Suppl 1):1716-1719.","DOI":"10.1182\/blood-2022-157326"},{"key":"51070","doi-asserted-by":"crossref","unstructured":"Davids MS, Kim HT, Costello C. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020; 135(24):2182-2191.","DOI":"10.1182\/blood.2019004710"},{"key":"51071","doi-asserted-by":"crossref","unstructured":"Wang AY, Kline J, Stock W. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020; 26(5):1025-1027.","DOI":"10.1016\/j.bbmt.2020.01.021"},{"key":"51072","doi-asserted-by":"crossref","unstructured":"Ravandi F, Assi R, Daver N. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019; 6(9):e480-e488.","DOI":"10.1016\/S2352-3026(19)30114-0"},{"key":"51073","doi-asserted-by":"crossref","unstructured":"Penter L, Liu Y, Wolff JO. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023; 141(15):1817-1830.","DOI":"10.1182\/blood.2022018246"},{"key":"51074","doi-asserted-by":"crossref","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020; 20(3):173-185.","DOI":"10.1038\/s41577-019-0224-6"},{"key":"51075","doi-asserted-by":"crossref","unstructured":"Majeti R, Chao MP, Alizadeh AA. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2):286-299.","DOI":"10.1016\/j.cell.2009.05.045"},{"key":"51076","doi-asserted-by":"crossref","unstructured":"Boumber Y, Kantarjian H, Jorgensen J. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012; 26(11):2428-2431.","DOI":"10.1038\/leu.2012.153"},{"key":"51077","doi-asserted-by":"crossref","unstructured":"Blum W, Sanford BL, Klisovic R. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017; 31(1):34-39.","DOI":"10.1038\/leu.2016.252"},{"key":"51078","doi-asserted-by":"crossref","unstructured":"Foran JM, Sun Z, Claxton DF. Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study. Blood. 2019; 134(Suppl_1):115.","DOI":"10.1182\/blood-2019-129876"},{"key":"51079","doi-asserted-by":"crossref","unstructured":"Borthakur G, Ravandi F, Patel K. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022; 97(11):1427-1434.","DOI":"10.1002\/ajh.26700"},{"key":"51080","doi-asserted-by":"crossref","unstructured":"Yin JAL, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012; 120(14):2826-2835.","DOI":"10.1182\/blood-2012-06-435669"},{"key":"51081","doi-asserted-by":"crossref","unstructured":"Senapati J, Shoukier M, Garcia-Manero G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022; 97(5):574-582.","DOI":"10.1002\/ajh.26496"},{"key":"51082","doi-asserted-by":"crossref","unstructured":"Bazinet A, Kantarjian H, Borthakur G. A phase II study of azacitidine plus venetoclax as maintenance therapy in acute myeloid leukemia: durable responses with longer term follow-up. Blood. 2022; 140(Suppl 1):9005-9007.","DOI":"10.1182\/blood-2022-162918"},{"key":"51083","doi-asserted-by":"crossref","unstructured":"Ivanov V, Yeh S-P, Mayer J. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol. 2022; 18(26):2879-2889.","DOI":"10.2217\/fon-2022-0450"},{"key":"51084","doi-asserted-by":"crossref","unstructured":"Oran B, Champlin RE, Thall PF. Phase II trial of venetoclax (Ven) in combination with azacitidine (AZA) as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation (SCT). Blood. 2022; 140(Suppl 1):10561-10562.","DOI":"10.1182\/blood-2022-159312"},{"key":"51085","doi-asserted-by":"crossref","unstructured":"Wei Y, Xiong X, Li X. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021; 112(9):3636-3644.","DOI":"10.1111\/cas.15048"},{"key":"51086","doi-asserted-by":"crossref","unstructured":"Ramsingh G, Westervelt P, Cashen AF. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia. 2013; 27(3):725-728.","DOI":"10.1038\/leu.2012.214"},{"key":"51087","doi-asserted-by":"crossref","unstructured":"Hunault M, Maillard N, Tanguy-Schmidt A. Safety and longterm efficacy of maintenance therapy with alternating azacytidine (AZA) and lenalidomide (Len) cycles in elderly (\u2265 60) fit patients (Pts) with poor prognosis AML in first complete remission (CR) after LIA induction. A phase II multicentric GOELAMS trial. Blood. 2015; 126(23):3787.","DOI":"10.1182\/blood.V126.23.3787.3787"},{"key":"51088","doi-asserted-by":"crossref","unstructured":"Wei A, Tan P, Perruzza S. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. Br J Haematol. 2015; 169(2):199-210.","DOI":"10.1111\/bjh.13281"},{"key":"51089","doi-asserted-by":"crossref","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-4860.","DOI":"10.1182\/blood-2013-01-466706"},{"key":"51090","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015; 16(16):1691-1699.","DOI":"10.1016\/S1470-2045(15)00362-9"},{"key":"51091","doi-asserted-by":"crossref","unstructured":"Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377(5):454-464.","DOI":"10.1056\/NEJMoa1614359"},{"key":"51092","unstructured":"Larson RA, Mandrekar SJ, Sanford BL. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017; 130(Suppl 1):145."},{"key":"51093","doi-asserted-by":"crossref","unstructured":"Schlenk RF, Weber D, Fiedler W. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019; 133(8):840-851.","DOI":"10.1182\/blood-2018-08-869453"},{"key":"51094","doi-asserted-by":"crossref","unstructured":"Perl AE, Martinelli G, Cortes JE. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019; 381(18):1728-1740.","DOI":"10.1056\/NEJMoa1902688"},{"key":"51095","doi-asserted-by":"crossref","unstructured":"Perl AE, Larson RA, Podoltsev NA. Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022; 139(23):3366-3375.","DOI":"10.1182\/blood.2021011583"},{"key":"51096","doi-asserted-by":"crossref","unstructured":"Erba H, Montesinos P, Vrhovac R. AML-029 quizartinib prolonged overall survival (OS) vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-internal tandem duplication positive (FLT3-ITD+) acute myeloid leukemia (AML). Clin Lymphoma, Myeloma Leuk. 2022; 22:S208-S209.","DOI":"10.1016\/S2152-2650(22)01212-5"},{"key":"51097","doi-asserted-by":"crossref","unstructured":"Montesinos P, Recher C, Vives S. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022; 386(16):1519-1531.","DOI":"10.1056\/NEJMoa2117344"},{"key":"51098","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Schuh AC, Stein EM. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021; 22(11):1597-1608.","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"51099","doi-asserted-by":"crossref","unstructured":"Stein EM, DiNardo CD, Fathi AT. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021; 137(13):1792-1803.","DOI":"10.1182\/blood.2020007233"},{"key":"51100","doi-asserted-by":"crossref","unstructured":"Paschka P, Schlenk RF, Weber D. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia - results of the AMLSG 11-08 trial. Leukemia. 2018; 32(7):1621-1630.","DOI":"10.1038\/s41375-018-0129-6"},{"key":"51101","doi-asserted-by":"crossref","unstructured":"Marcucci G, Geyer S, Laumann K. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020; 4(4):696-705.","DOI":"10.1182\/bloodadvances.2019000492"},{"key":"51102","doi-asserted-by":"crossref","unstructured":"Senapati J, Abuasab T, Haddad FG. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023; 98(3):E53-E56.","DOI":"10.1002\/ajh.26811"},{"key":"51103","doi-asserted-by":"crossref","unstructured":"Zeidner JF, Vincent BG, Ivanova A. Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia. Blood Cancer Discov. 2021; 2(6):616-629.","DOI":"10.1158\/2643-3230.BCD-21-0070"},{"key":"51104","doi-asserted-by":"crossref","unstructured":"Zheng F, Li Q, Yang S. Maintenance therapy with combination of azacitidine, danazol and thalidomide after intensive chemotherapy in acute myeloid leukemia patients. Blood. 2022; 140(Suppl 1):11720-11722.","DOI":"10.1182\/blood-2022-164675"},{"key":"51105","doi-asserted-by":"crossref","unstructured":"Pigneux A, B\u00e9n\u00e9 MC, Guardiola P. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol. 2017; 35(4):387-393.","DOI":"10.1200\/JCO.2016.67.6213"},{"key":"51106","doi-asserted-by":"crossref","unstructured":"Ocio EM, Herrera P, Olave MT. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib\/II panobidara study. Haematologica. 2015; 100(10):1294-1300.","DOI":"10.3324\/haematol.2015.129577"},{"key":"51107","doi-asserted-by":"crossref","unstructured":"Burchert A, Bug G, Fritz LV. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002.","DOI":"10.1200\/JCO.19.03345"},{"key":"51108","doi-asserted-by":"crossref","unstructured":"Xuan L, Wang Y, Huang F. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020; 21(9):1201-1212.","DOI":"10.1016\/S1470-2045(20)30455-1"},{"key":"51109","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Levis M, Patnaik MM. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021; 56(5):1180-1189.","DOI":"10.1038\/s41409-020-01153-1"},{"key":"51110","doi-asserted-by":"crossref","unstructured":"Terao T, Matsuoka K-i, Ueda H. Gilteritinib maintenance therapy post-allogenic stem-cell transplantation improves the prognosis of patients with FLT3-mutated AML. Blood. 2022; 140(Suppl 1):3290-3291.","DOI":"10.1182\/blood-2022-163876"},{"key":"51111","doi-asserted-by":"crossref","unstructured":"Levis MJ, Hamadani M, Logan BR. BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. Blood. 2019; 134(Suppl_1):4602.","DOI":"10.1182\/blood-2019-124322"},{"key":"51112","unstructured":"Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib [press release]. Tokyo and Rockville, Maryland: Astellas Pharma Inc. and BMT CTN March 9. 2023."},{"key":"51113","doi-asserted-by":"crossref","unstructured":"Cortes JE, Khaled S, Martinelli G. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019; 20(7):984-997.","DOI":"10.1016\/S1470-2045(19)30150-0"},{"key":"51114","doi-asserted-by":"crossref","unstructured":"Senapati J, Kadia TM. Which FLT3 inhibitor for treatment of AML?. Curr Treat Options Oncol. 2022; 23(3):359-380.","DOI":"10.1007\/s11864-022-00952-6"},{"key":"51115","doi-asserted-by":"crossref","unstructured":"Fathi AT, Kim HT, Soiffer RJ. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022; 6(22):5857-5865.","DOI":"10.1182\/bloodadvances.2022008632"},{"key":"51116","doi-asserted-by":"crossref","unstructured":"Oran B, de Lima M, Garcia-Manero G. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020; 4(21):5580-5588.","DOI":"10.1182\/bloodadvances.2020002544"},{"key":"51117","doi-asserted-by":"crossref","unstructured":"de Lima M, Oran B, Papadopoulos EB. CC-486 (oral azacitidine) maintenance therapy is well tolerated after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Biology Blood Marrow Transplant. 2016; 22(3):S312-S313.","DOI":"10.1016\/j.bbmt.2015.11.784"},{"key":"51118","doi-asserted-by":"crossref","unstructured":"Kungwankiattichai S, Ponvilawan B, Roy C, Tunsing P, Kuchenbauer F, Owattanapanich W. Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:801632.","DOI":"10.3389\/fmed.2022.801632"},{"key":"51119","doi-asserted-by":"crossref","unstructured":"Mishra A, Tamari R, DeZern AE. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022; 40(34):3985-3993.","DOI":"10.1200\/JCO.22.00181"},{"key":"51120","doi-asserted-by":"crossref","unstructured":"Biederst\u00e4dt A, Rezvani K. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy. Blood. 2023; 141(1):22-38.","DOI":"10.1182\/blood.2021012411"},{"key":"51121","doi-asserted-by":"crossref","unstructured":"Schmid C, Labopin M, Schaap N. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplant. 2022; 57(2):215-223.","DOI":"10.1038\/s41409-021-01515-3"},{"key":"51122","doi-asserted-by":"crossref","unstructured":"Schmid C, Schleuning M, Tischer J. Early allo-SCT for AML with a complex aberrant karyotype - results from a prospective pilot study. Bone Marrow Transplant. 2012; 47(1):46-53.","DOI":"10.1038\/bmt.2011.15"},{"key":"51123","doi-asserted-by":"crossref","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23(24):5675-5687.","DOI":"10.1200\/JCO.2005.07.061"},{"key":"51124","doi-asserted-by":"crossref","unstructured":"Jedlickova Z, Schmid C, Koenecke C. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016; 51(5):663-667.","DOI":"10.1038\/bmt.2015.234"},{"key":"51125","doi-asserted-by":"crossref","unstructured":"Tsirigotis P, Byrne M, Schmid C. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51(11):1431-1438.","DOI":"10.1038\/bmt.2016.167"},{"key":"51126","doi-asserted-by":"crossref","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020; 130(4):1552-1564.","DOI":"10.1172\/JCI129204"},{"key":"51127","doi-asserted-by":"crossref","unstructured":"Barbullushi K, Rampi N, Serpenti F. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers (Basel). 2022; 14(12):2994.","DOI":"10.3390\/cancers14122994"},{"key":"51128","doi-asserted-by":"crossref","unstructured":"Fujii S-i, Kawamata T, Shimizu K. Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML. Mol Ther Oncolytics. 2022; 27:315-332.","DOI":"10.1016\/j.omto.2022.09.001"},{"key":"51129","doi-asserted-by":"crossref","unstructured":"Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol. 2015; 6:36.","DOI":"10.3389\/fimmu.2015.00036"},{"key":"51130","doi-asserted-by":"crossref","unstructured":"Anguille S, Van de Velde AL, Smits EL. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017; 130(15):1713-1721.","DOI":"10.1182\/blood-2017-04-780155"},{"key":"51131","doi-asserted-by":"crossref","unstructured":"Maslak PG, Dao T, Bernal Y. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018; 2(3):224-234.","DOI":"10.1182\/bloodadvances.2017014175"},{"key":"51132","doi-asserted-by":"crossref","unstructured":"Kreutmair S, Pfeifer D, Waterhouse M. First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience. Cancer Immunol Immunother. 2022; 71(12):2913-2928.","DOI":"10.1007\/s00262-022-03202-8"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281810\/75607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281810\/75930","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11073\/75607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:01Z","timestamp":1794045841000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":123,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281810","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,4]]}}}